Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Polyrizon Ltd. ( (PLRZ) ) has shared an update.
On February 6, 2026, Polyrizon Ltd. announced it had signed a development agreement with Clearmind Medicine Inc. to create a proprietary intranasal formulation of MEAI, Clearmind’s next-generation, non-hallucinogenic neuroplastogen drug candidate for treating addiction-related and other central nervous system conditions. The collaboration aims to harness Polyrizon’s intranasal delivery platforms, which offer enhanced nasal residence time, targeted delivery, and potential pharmacokinetic advantages over oral administration, positioning Polyrizon as an emerging specialist partner in intranasal drug delivery and potentially strengthening both companies’ roles in the evolving neuroplasticity-focused therapeutics market.
More about Polyrizon Ltd.
Polyrizon Ltd. is a pre-clinical-stage biotechnology company specializing in innovative intranasal medical device hydrogels delivered as nasal sprays, designed to form a thin hydrogel-based barrier in the nasal cavity that can protect against viruses and allergens. Its proprietary Capture and Contain (C&C) technology functions as a “biological mask”, while its earlier-stage Trap and Target (T&T) platform focuses on intranasal delivery of active pharmaceutical ingredients to enhance bioadhesion and prolonged retention at the nasal deposition site.
Average Trading Volume: 3,213,239
Technical Sentiment Signal: Sell
Current Market Cap: $21.31M
See more data about PLRZ stock on TipRanks’ Stock Analysis page.